Form 4: Third Rock Ventures Sells $4M in Tango Therapeutics Stock

Third Rock Ventures IV, a significant shareholder and director group, reported the sale of 500,000 shares of Tango Therapeutics common stock for approximately $4 million.

Summary

• Third Rock Ventures IV, L.P., along with its general partners Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC, reported a sale of Tango Therapeutics, Inc. common stock.
• The transaction involved the disposition of 500,000 shares of common stock on September 25, 2025.
• The shares were sold at a weighted average price of $8.017 per share, with individual transaction prices ranging from $8.00 to $8.165.
• The total value of the shares sold amounts to approximately $4,008,500.
• Following this transaction, Third Rock Ventures IV, L.P. directly holds 13,863,975 shares of Tango Therapeutics common stock.
• The sale was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 4

Explanation: A significant insider sale by a major institutional investor and director group, even if pre-planned, typically carries a negative sentiment as it suggests a reduction in conviction or profit-taking. However, the remaining stake is still substantial, preventing a lower score.

Negatives

• A significant insider sale by a 10% owner and director group could be interpreted by the market as a reduction in conviction or a move to realize profits.
• The sale of 500,000 shares represents a notable divestment from a key institutional investor.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: The sale by a director and 10% owner could raise questions about internal perceptions of future growth, though the 10b5-1 plan mitigates immediate concerns.

Key Dates

Recommendation

While the insider sale by Third Rock Ventures is a notable event and typically viewed negatively, the transaction was executed under a pre-arranged 10b5-1 plan, which suggests it was not a reaction to immediate adverse news. Furthermore, Third Rock Ventures retains a substantial beneficial ownership of over 13.8 million shares, indicating continued, albeit reduced, commitment. Investors should monitor future developments and company performance rather than reacting solely to this pre-scheduled sale.

Keywords

Tango Therapeutics, TNGX, Third Rock Ventures, Insider Sale, Form 4, Stock Transaction, Biotechnology, Venture Capital